$GALT - Galectin Therapeutics: FDA cleared a single-trial path to approval. The company can't afford to run it.
Galectin Therapeutics (GALT) is a clinical-stage biotech with one drug, belapectin, for MASH cirrhosis with portal hypertension (severe liver scarring plus dangerous high blood pressure in the liver's veins). Stock jumped over 25% on June 24 after the company announced …